Quarterly report pursuant to Section 13 or 15(d)

Basic and Diluted Net Loss Per Share (Tables)

v3.20.2
Basic and Diluted Net Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share for:

 

    Three-months ended September 30, 2020  
    (Unaudited)  
    Net Loss (Numerator)     Shares (Denominator)     Per share
amount
 
Basic loss per share   $ (1,354,331 )     755,847     $ (1.79 )
Effect of dilutive securities—Common stock options, warrants, and convertible notes     -       -       -  
Diluted loss per share   $ (1,354,331 )     755,847     $ (1.79 )

 

    Three-months ended September 30, 2019  
    (Unaudited)  
    Net Loss (Numerator)     Shares (Denominator)     Per share
amount
 
Basic loss per share   $ (1,433,626 )     683,731     $ (2.10 )
Effect of dilutive securities—Common stock options, warrants, and convertible notes     -       -       -  
Diluted loss per share   $ (1,433,626 )     683,731     $ (2.10 )

 

    Nine-months ended September 30, 2020  
    (Unaudited)  
    Net Loss (Numerator)     Shares (Denominator)     Per share
amount
 
Basic loss per share   $ (4,057,541 )     736,719     $ (5.51 )
Effect of dilutive securities—Common stock options, warrants, and convertible notes     -       -       -  
Diluted loss per share   $ (4,057,541 )     736,719     $ (5.51 )

 

    Nine-months ended September 30, 2019  
    (Unaudited)  
    Net Loss (Numerator)     Shares (Denominator)     Per share
amount
 
Basic loss per share   $ (3,650,740 )     678,108     $ (5.38 )
Effect of dilutive securities—Common stock options, warrants, and convertible notes     -       -       -  
Diluted loss per share   $ (3,650,740 )     678,108     $ (5.38 )

Schedule of Shares of Common Stock Equivalents Were Excluded from Computation of Diluted Net Loss Per Share

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the periods ended:

 

    September 30, 2020     September 30, 2019  
      (Unaudited)       (Unaudited)  
Common stock underlying convertible notes     549,527       47,012  
Common stock underlying options     171,969       202,246  
Common stock underlying warrants     631,878       513,875  
Total common stock equivalents     1,353,374       763,133